Discover open access scientific publications

Search, annotate, share and cite publications

Publications by M. Wang

P2.13-05 Real-World Clinical Benefit of Continuing Crizotinib Beyond Progression Disease (CBPD) in Patients With Advanced ALK-Positive NSCLC.

Journal of Thoracic Oncology

English

OA10.07 Resistance Mechanisms of Osimertinib in Chinese Non-Small Cell Lung Cancer Patients: Analysis From AURA17 Trial

Journal of Thoracic Oncology

English

P3.01-49 Effciency of Low-Dosage Apatinib Monotherapy in Treatment of Advanced Lung Squamous Cell Carcinoma

Journal of Thoracic Oncology

English

P2.17-30 Serum Lipoprotein(A) Correlates With the Effect of Endostar Combined With Concurrent Chemoradiotherapy in Patients With Locally Advanced LSCC

Journal of Thoracic Oncology

English

P1.01-108 Management of Anlotinib-Related Adverse Events: Data From ALTER 0303

Journal of Thoracic Oncology

English

Neural Correlates of Covert Face Processing: fMRI Evidence From a Prosopagnosic Patient

Cerebral Cortex

Molecular Neuroscience

Cellular

Cognitive Neuroscience

2013

English

P1.01-107 the Impact of Anlotinib on Quality of Life in Patients With Advance NSCLC: Post-Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303)

Journal of Thoracic Oncology

English

P3.03-07 Co-Occurring Genomic Alterations in EGFR Altered Chinese Lung Adenocarcinoma Patients

Journal of Thoracic Oncology

English

Parameterizing Deep Convection Using the Assumed Probability Density Function Method

Geoscientific Model Development

English

P2.03-041 the Concentration of Avitinib in Cerebrospinal Fluid and Its Efficacy and Safety in NSCLC Patients With T790M Mutation

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by M. Wang

P2.13-05 Real-World Clinical Benefit of Continuing Crizotinib Beyond Progression Disease (CBPD) in Patients With Advanced ALK-Positive NSCLC.

OA10.07 Resistance Mechanisms of Osimertinib in Chinese Non-Small Cell Lung Cancer Patients: Analysis From AURA17 Trial

P3.01-49 Effciency of Low-Dosage Apatinib Monotherapy in Treatment of Advanced Lung Squamous Cell Carcinoma

P2.17-30 Serum Lipoprotein(A) Correlates With the Effect of Endostar Combined With Concurrent Chemoradiotherapy in Patients With Locally Advanced LSCC

P1.01-108 Management of Anlotinib-Related Adverse Events: Data From ALTER 0303

Neural Correlates of Covert Face Processing: fMRI Evidence From a Prosopagnosic Patient

P1.01-107 the Impact of Anlotinib on Quality of Life in Patients With Advance NSCLC: Post-Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303)

P3.03-07 Co-Occurring Genomic Alterations in EGFR Altered Chinese Lung Adenocarcinoma Patients

Parameterizing Deep Convection Using the Assumed Probability Density Function Method

P2.03-041 the Concentration of Avitinib in Cerebrospinal Fluid and Its Efficacy and Safety in NSCLC Patients With T790M Mutation